A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumours|Endometrial Cancer|Cervical Cancer|Ovarian Cancer|Breast Cancer|Triple Negative Breast Cancer (TNBC)|HER2-negative Breast Cancer|Head and Neck Squamous Cell Carcinoma (HNSCC)|Adrenocortical Carcinoma|Uveal Melanoma
Interventions: DRUG: [111In]-FPI-1547 Injection|DRUG: [225Ac]-FPI-1434 Injection multi-dose|BIOLOGICAL: FPI-1175 Infusion|DRUG: [225Ac]-FPI-1434 Injection single-dose
Sponsor: Fusion Pharmaceuticals Inc.